Equities

Genetic Signatures Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GSS:ASX

Genetic Signatures Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.145
  • Today's Change0.00 / 0.00%
  • Shares traded83.52k
  • 1 Year change-74.22%
  • Beta0.7103
Data delayed at least 20 minutes, as of Feb 06 2026 04:33 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.

  • Revenue in AUD (TTM)21.36m
  • Net income in AUD-20.10m
  • Incorporated2001
  • Employees--
  • Location
    Genetic Signatures LtdHeart Research Institute7 Eliza Street NewtownSYDNEY 2042AustraliaAUS
  • Phone+61 29870-7580
  • Fax+61 29240-9821
  • Websitehttps://geneticsignatures.com/au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ReNerve Ltd271.71k-3.73m16.50m----3.29--60.72-0.0262-0.02620.00190.0365----------------90.05---1,374.23--6.10-34.480.00--53.19---25.09------
Memphasys Ltd3.70k-5.04m18.81m24.00--3.36--5,083.96-0.0022-0.00220.000.00210.00030.35150.0037---42.63-26.29-85.43-37.53-961.89---136,191.30-16,363.590.1934-6.140.5451---93.83--6.19---23.54--
Resonance Health Ltd11.16m-1.73m22.32m18.00--2.30--2.00-0.0038-0.00380.02450.02040.5848--3.82---9.08-4.17-12.91-4.98-----15.53-9.03---6.570.2882--26.7824.65-1,123.59--19.97--
Control Bionics Ltd7.04m-6.11m24.31m----3.22--3.45-0.0232-0.02320.02610.01830.81584.993.35---70.78-48.07-99.30-55.8071.1468.24-86.77-98.271.08-33.300.0733--16.7616.36-3.30--7.93--
ImExHS Ltd26.35m-4.11m25.40m400.00--1.75--0.9642-0.0861-0.08610.55920.26931.1877.603.3265,869.38-18.42-17.16-27.27-22.8834.4432.57-15.61-21.021.51-10.770.0863--34.4127.4741.00---9.90--
CONNEQT Health Ltd3.55m-18.19m27.56m26.00--39.07--7.75-0.0507-0.05070.010.00120.32350.438910.72---165.59-99.31-618.20-249.1671.9784.29-511.88-208.530.6557-2.370.8527---68.20-5.10-168.93---33.92--
Atomo Diagnostics Ltd3.79m-4.97m32.41m----4.24--8.55-0.0077-0.00770.00590.00940.36721.072.83---48.13-30.62-57.46-33.1050.6240.54-131.08-113.092.27--0.0259---10.53-6.7227.41---55.73--
Genetic Signatures Ltd21.36m-20.10m32.94m----0.6575--1.54-0.0899-0.08990.09420.22050.35051.176.04---32.98-16.72-35.71-18.3156.7255.89-94.10-38.679.49-143.040.0156--49.698.55-12.55---17.43--
Curvebeam AI Ltd12.10m-16.84m36.96m50.00--0.8728--3.06-0.0453-0.04530.03230.09050.19460.634310.20---27.10---31.21--44.89---139.24--1.22-80.930.3366--85.33--27.09------
ImpediMed Ltd12.72m-23.24m38.74m77.00--1.88--3.04-0.0115-0.01150.00630.01010.28712.165.51165,246.80-52.43-42.33-59.33-48.4986.2585.16-182.62-195.144.71-112.780.4142--23.3117.25-17.42---14.47--
Vitasora Health Ltd3.71m-10.11m40.88m2.00--2.37--11.03-0.0071-0.00710.00270.00930.30130.01064.17---82.17-118.94-115.44-176.5499.1978.72-272.73-533.630.6694--0.0039--256.7710.92-41.74------
BCAL Diagnostics Ltd2.65m-7.24m42.33m----6.77--15.97-0.0201-0.02010.00740.0170.239--0.9573---65.31-57.98-87.92-72.00-----273.21-249.54----0.2766---13.0143.11-13.14--190.46--
HeraMED Ltd322.93k-4.53m44.55m----60.80--137.94-0.0059-0.00590.00040.00070.13810.37941.57---193.87-129.03-316.53-221.1458.7058.67-1,404.05-2,178.902.33--0.468---39.9011.7418.96------
Nova Eye Medical Ltd29.27m-9.06m48.42m130.00--2.55--1.65-0.0373-0.03730.11830.06681.042.927.08---32.13-21.38-39.78-24.9764.5478.66-30.95-46.441.85-121.420.1372--24.8117.95-3.06---14.69--
Data as of Feb 06 2026. Currency figures normalised to Genetic Signatures Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

50.74%Per cent of shares held by top holders
HolderShares% Held
Perennial Value Management Ltd.as of 19 Aug 202533.48m14.74%
Regal Funds Management Pty Ltd.as of 19 Aug 202520.14m8.87%
Mercer Investments (Australia) Ltd.as of 24 Nov 202519.86m8.74%
FIL Investment Management (Hong Kong) Ltd.as of 19 Aug 202518.34m8.08%
Pengana Capital Ltd.as of 29 Aug 202510.99m4.84%
Norges Bank Investment Managementas of 30 Jun 20256.81m3.00%
FIL Pensions Managementas of 30 Jun 20253.16m1.39%
Mirrabooka Investments Ltd. (Investment Management)as of 19 Aug 20252.16m0.95%
DFA Australia Ltd.as of 31 Dec 2025310.33k0.14%
Dimensional Fund Advisors LPas of 31 Oct 202513.55k0.01%
More ▼
Data from 30 Jun 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.